Clinical trial

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

NCT04418648

Study summary

ClinicalTrials.gov

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Toripalimab Normalized identity: toripalimab View linked drug · Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-06-01

PhasePHASE2

Conditions

Small Cell Lung Cancer Limited Stageunresolved

Interventions

ToripalimabDRUG · verified · RxNorm: toripalimab

Sponsors & collaborators

Sun Yat-sen Universitylead sponsor

The First Affiliated Hospital of Guangzhou Medical Universitycollaborator

Guangzhou Panyu Central Hospitalcollaborator

Mapped research locations

GuangzhouChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04418648 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.